ReP USP - Resultado da busca

Artigo de periodico
Enhanced elimination of betamethasone in dichorionic twin pregnancies (2022)
Rodrigues, Grazielle de Fátima Pinto ; Benzi, Jhohann Richard de Lima ; Matos, Luísa Helena de Castro; Freitas, Stella Felippe de; Marques, Maria Paula ; Cavalli, Ricardo de Carvalho; Moisés, Elaine Christine Dantas ; Duarte, Geraldo; Lanchote, Vera Lucia ; Marcolin, Alessandra Cristina
Source: British Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP
Subjects: GRAVIDEZ, FARMACOCINÉTICA, PLACENTA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODRIGUES, Grazielle de Fátima Pinto et al. Enhanced elimination of betamethasone in dichorionic twin pregnancies. British Journal of Clinical Pharmacology, v. 88, n. 4, p. 1897-1903, 2022Tradução . . Disponível em: https://doi.org/10.1111/bcp.15111. Acesso em: 17 nov. 2024.
APA
Rodrigues, G. de F. P., Benzi, J. R. de L., Matos, L. H. de C., Freitas, S. F. de, Marques, M. P., Cavalli, R. de C., et al. (2022). Enhanced elimination of betamethasone in dichorionic twin pregnancies. British Journal of Clinical Pharmacology, 88( 4), 1897-1903. doi:10.1111/bcp.15111
NLM
Rodrigues G de FP, Benzi JR de L, Matos LH de C, Freitas SF de, Marques MP, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL, Marcolin AC. Enhanced elimination of betamethasone in dichorionic twin pregnancies [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 4): 1897-1903.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1111/bcp.15111
Vancouver
Rodrigues G de FP, Benzi JR de L, Matos LH de C, Freitas SF de, Marques MP, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL, Marcolin AC. Enhanced elimination of betamethasone in dichorionic twin pregnancies [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 4): 1897-1903.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1111/bcp.15111
Artigo de periodico
Chromatographic profile, in silico and in vivo study of the pharmacokinetic and toxicological properties of major constituent present in kefir, the kefiran (2022)
Barros, Susy Érika de Lima; Lima, Henrique Barros de; Gonçalves, Leandra Karoline Alves; Correia, Lenir Cabral; Brito, Maiara de Fátima de Brito; Barcelos, Mariana Pegrucci ; Silva, Guilherme Martins da ; Silva, Carlos Henrique Tomich de Paula da ; Costa, Rafael Garrett da; Cruz, Rodrigo Alves Soares; Carvalho, José Carlos Tavares; Melim, Lorane Izabel da Silva Hage
Source: Toxicology Research. Unidades: FCFRP, FFCLRP
Subjects: ALIMENTOS FUNCIONAIS, POLISSACARÍDEOS, FARMACOCINÉTICA, LEVEDURAS, BACTÉRIAS LÁTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BARROS, Susy Érika de Lima et al. Chromatographic profile, in silico and in vivo study of the pharmacokinetic and toxicological properties of major constituent present in kefir, the kefiran. Toxicology Research, v. 11, n. 3, p. 520-528, 2022Tradução . . Disponível em: https://doi.org/10.1093/toxres/tfac032. Acesso em: 17 nov. 2024.
APA
Barros, S. É. de L., Lima, H. B. de, Gonçalves, L. K. A., Correia, L. C., Brito, M. de F. de B., Barcelos, M. P., et al. (2022). Chromatographic profile, in silico and in vivo study of the pharmacokinetic and toxicological properties of major constituent present in kefir, the kefiran. Toxicology Research, 11( 3), 520-528. doi:10.1093/toxres/tfac032
NLM
Barros SÉ de L, Lima HB de, Gonçalves LKA, Correia LC, Brito M de F de B, Barcelos MP, Silva GM da, Silva CHT de P da, Costa RG da, Cruz RAS, Carvalho JCT, Melim LI da SH. Chromatographic profile, in silico and in vivo study of the pharmacokinetic and toxicological properties of major constituent present in kefir, the kefiran [Internet]. Toxicology Research. 2022 ; 11( 3): 520-528.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1093/toxres/tfac032
Vancouver
Barros SÉ de L, Lima HB de, Gonçalves LKA, Correia LC, Brito M de F de B, Barcelos MP, Silva GM da, Silva CHT de P da, Costa RG da, Cruz RAS, Carvalho JCT, Melim LI da SH. Chromatographic profile, in silico and in vivo study of the pharmacokinetic and toxicological properties of major constituent present in kefir, the kefiran [Internet]. Toxicology Research. 2022 ; 11( 3): 520-528.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1093/toxres/tfac032
Artigo de periodico
Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics (2022)
Pavan, Marcella; Yamamoto, Priscila; Silva, Rodrigo Moreira da; Salgado Junior, Wilson; Santos, José dos; Kemp, Rafael; Sankarankutty, Ajith Kumar ; Moraes, Natália de; Gaitani, Cristiane de
Source: Journal of Chromatography B. Unidades: FCFRP, FMRP
Subjects: QUIMIOMETRIA, CROMATOGRAFIA LÍQUIDA, ESPECTROMETRIA DE MASSAS, REPRODUTIBILIDADE DE RESULTADOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PAVAN, Marcella et al. Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics. Journal of Chromatography B, v. 1205, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2022.123338. Acesso em: 17 nov. 2024.
APA
Pavan, M., Yamamoto, P., Silva, R. M. da, Salgado Junior, W., Santos, J. dos, Kemp, R., et al. (2022). Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics. Journal of Chromatography B, 1205. doi:10.1016/j.jchromb.2022.123338
NLM
Pavan M, Yamamoto P, Silva RM da, Salgado Junior W, Santos J dos, Kemp R, Sankarankutty AK, Moraes N de, Gaitani C de. Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics [Internet]. Journal of Chromatography B. 2022 ; 1205[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/j.jchromb.2022.123338
Vancouver
Pavan M, Yamamoto P, Silva RM da, Salgado Junior W, Santos J dos, Kemp R, Sankarankutty AK, Moraes N de, Gaitani C de. Chemometric optimization of salting-out assisted liquid–liquid extraction (SALLE) combined with LC-MS/MS for the analysis of carvedilol enantiomers in human plasma: application to clinical pharmacokinetics [Internet]. Journal of Chromatography B. 2022 ; 1205[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/j.jchromb.2022.123338
Artigo de periodico
Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort (2022)
Ximenez, João Paulo Bianchi; Elias, Anna Beatriz Ribeiro; Nardotto, Glauco Henrique Balthazar ; Barroso, Paulo Feijó; Bollela, Valdes Roberto; Lanchote, Vera Lucia ; Suarez-Kurtz, Guilherme
Source: British Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP
Subjects: FARMACOCINÉTICA, HIV, CITOCROMO P-450, GENÓTIPOS, INFECÇÕES POR HIV, FARMACOGENÉTICA, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
XIMENEZ, João Paulo Bianchi et al. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort. British Journal of Clinical Pharmacology, v. 88, n. 10, p. 4585-4594, 2022Tradução . . Disponível em: https://doi.org/10.1111/bcp.15387. Acesso em: 17 nov. 2024.
APA
Ximenez, J. P. B., Elias, A. B. R., Nardotto, G. H. B., Barroso, P. F., Bollela, V. R., Lanchote, V. L., & Suarez-Kurtz, G. (2022). Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort. British Journal of Clinical Pharmacology, 88( 10), 4585-4594. doi:10.1111/bcp.15387
NLM
Ximenez JPB, Elias ABR, Nardotto GHB, Barroso PF, Bollela VR, Lanchote VL, Suarez-Kurtz G. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 10): 4585-4594.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1111/bcp.15387
Vancouver
Ximenez JPB, Elias ABR, Nardotto GHB, Barroso PF, Bollela VR, Lanchote VL, Suarez-Kurtz G. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 10): 4585-4594.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1111/bcp.15387
Artigo de periodico
No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients (2022)
Nardotto, Glauco Henrique Balthazar ; Bollela, Valdes Roberto; Rocha, Adriana; Della Pasqua, Oscar; Lanchote, Vera Lucia
Source: Clinical and Translational Science. Unidades: FMRP, FCFRP
Subjects: HIV, FARMACOCINÉTICA, TUBERCULOSE, ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NARDOTTO, Glauco Henrique Balthazar et al. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, v. 15, p. 514-523, 2022Tradução . . Disponível em: https://doi.org/10.1111/cts.13169. Acesso em: 17 nov. 2024.
APA
Nardotto, G. H. B., Bollela, V. R., Rocha, A., Della Pasqua, O., & Lanchote, V. L. (2022). No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, 15, 514-523. doi:10.1111/cts.13169
NLM
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ; 15 514-523.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1111/cts.13169
Vancouver
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ; 15 514-523.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1111/cts.13169
Tese (Doutorado)
Atividade dos transportadores de ânions orgânicos 1 e 3 empregando a farmacocinética da furosemida: impactos da gestação e da pielonefrite aguda (2022)
Benzi, Jhohann Richard de Lima ; Lanchote, Vera Lucia (Orientador)
Unidade: FCFRP
Subjects: FARMACOCINÉTICA, GRAVIDEZ, NEFRITE, MULHERES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BENZI, Jhohann Richard de Lima. Atividade dos transportadores de ânions orgânicos 1 e 3 empregando a farmacocinética da furosemida: impactos da gestação e da pielonefrite aguda. 2022. Tese (Doutorado) – Universidade de São Paulo, Ribeirão Preto, 2022. Disponível em: https://www.teses.usp.br/teses/disponiveis/60/60134/tde-19072023-154819/. Acesso em: 17 nov. 2024.
APA
Benzi, J. R. de L. (2022). Atividade dos transportadores de ânions orgânicos 1 e 3 empregando a farmacocinética da furosemida: impactos da gestação e da pielonefrite aguda (Tese (Doutorado). Universidade de São Paulo, Ribeirão Preto. Recuperado de https://www.teses.usp.br/teses/disponiveis/60/60134/tde-19072023-154819/
NLM
Benzi JR de L. Atividade dos transportadores de ânions orgânicos 1 e 3 empregando a farmacocinética da furosemida: impactos da gestação e da pielonefrite aguda [Internet]. 2022 ;[citado 2024 nov. 17 ] Available from: https://www.teses.usp.br/teses/disponiveis/60/60134/tde-19072023-154819/
Vancouver
Benzi JR de L. Atividade dos transportadores de ânions orgânicos 1 e 3 empregando a farmacocinética da furosemida: impactos da gestação e da pielonefrite aguda [Internet]. 2022 ;[citado 2024 nov. 17 ] Available from: https://www.teses.usp.br/teses/disponiveis/60/60134/tde-19072023-154819/
Artigo de periodico
Identification of novel potential cyclooxygenase-2 inhibitors using ligand- and structure-based virtual screening approaches (2022)
Cruz, Josiane Viana; Giuliatti, Silvana ; Alves, Levy Bueno ; Silva, Rai Campos ; Ferreira, Elenilze Figueiredo Batista; Kimani, Njogu M.; Silva, Carlos Henrique Tomich de Paula da ; Souza, João S. N. de; Espejo-Román, José M.; Santos, Cleydson Breno Rodrigues dos
Source: Journal of Biomolecular Structure and Dynamics. Unidades: FMRP, FCFRP, FFCLRP
Subjects: FARMACOCINÉTICA, TOXICOLOGIA, METABOLISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRUZ, Josiane Viana et al. Identification of novel potential cyclooxygenase-2 inhibitors using ligand- and structure-based virtual screening approaches. Journal of Biomolecular Structure and Dynamics, v. 40, n. 12, p. 5386-5408, 2022Tradução . . Disponível em: https://doi.org/10.1080/07391102.2020.1871413. Acesso em: 17 nov. 2024.
APA
Cruz, J. V., Giuliatti, S., Alves, L. B., Silva, R. C., Ferreira, E. F. B., Kimani, N. M., et al. (2022). Identification of novel potential cyclooxygenase-2 inhibitors using ligand- and structure-based virtual screening approaches. Journal of Biomolecular Structure and Dynamics, 40( 12), 5386-5408. doi:10.1080/07391102.2020.1871413
NLM
Cruz JV, Giuliatti S, Alves LB, Silva RC, Ferreira EFB, Kimani NM, Silva CHT de P da, Souza JSN de, Espejo-Román JM, Santos CBR dos. Identification of novel potential cyclooxygenase-2 inhibitors using ligand- and structure-based virtual screening approaches [Internet]. Journal of Biomolecular Structure and Dynamics. 2022 ; 40( 12): 5386-5408.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1080/07391102.2020.1871413
Vancouver
Cruz JV, Giuliatti S, Alves LB, Silva RC, Ferreira EFB, Kimani NM, Silva CHT de P da, Souza JSN de, Espejo-Román JM, Santos CBR dos. Identification of novel potential cyclooxygenase-2 inhibitors using ligand- and structure-based virtual screening approaches [Internet]. Journal of Biomolecular Structure and Dynamics. 2022 ; 40( 12): 5386-5408.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1080/07391102.2020.1871413
Artigo de periodico
Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model (2021)
Pinto, Leonardo Santos Ribeiro; Bapat, Priya; Moreira, Fernanda de Lima; Lubetsky, Angelika; Cavalli, Ricardo de Carvalho; Berger, Howard; Lanchote, Vera Lucia ; Koren, Gideon
Source: Pharmaceutical Research. Unidades: FCFRP, FMRP
Subjects: ANTAGONISTAS, FARMACOTERAPIA, ANTIDEPRESSIVOS, PLACENTA, COMPLICAÇÕES NA GRAVIDEZ, ANTI-HISTAMÍNICOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, v. 38, n. 4, p. 647-655, 2021Tradução . . Disponível em: https://doi.org/10.1007/s11095-021-03035-7. Acesso em: 17 nov. 2024.
APA
Pinto, L. S. R., Bapat, P., Moreira, F. de L., Lubetsky, A., Cavalli, R. de C., Berger, H., et al. (2021). Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, 38( 4), 647-655. doi:10.1007/s11095-021-03035-7
NLM
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Vancouver
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Artigo de periodico
Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers (2021)
Di Filippo, Leonardo Delello; Azambuja, Juliana Hofstäter; Dutra, Jessyca Aparecida Paes; Luiz, Marcela Tavares ; Duarte, Jonatas Lobato; Nicoleti, Luiza Ribeiro; Saad, Sara Teresinha Olalla; Chorilli, Marlus
Source: European Journal of Pharmaceutics and Biopharmaceutics. Unidade: FCFRP
Subjects: ANTINEOPLÁSICOS, NEOPLASIAS CEREBRAIS, FARMACOCINÉTICA, FARMACOTERAPIA, SISTEMAS DE DISTRIBUIÇÃO DE MEDICAMENTOS, NANOPARTÍCULAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DI FILIPPO, Leonardo Delello et al. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. European Journal of Pharmaceutics and Biopharmaceutics, v. 168, p. 76-89, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.ejpb.2021.08.011. Acesso em: 17 nov. 2024.
APA
Di Filippo, L. D., Azambuja, J. H., Dutra, J. A. P., Luiz, M. T., Duarte, J. L., Nicoleti, L. R., et al. (2021). Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. European Journal of Pharmaceutics and Biopharmaceutics, 168, 76-89. doi:10.1016/j.ejpb.2021.08.011
NLM
Di Filippo LD, Azambuja JH, Dutra JAP, Luiz MT, Duarte JL, Nicoleti LR, Saad STO, Chorilli M. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2021 ; 168 76-89.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/j.ejpb.2021.08.011
Vancouver
Di Filippo LD, Azambuja JH, Dutra JAP, Luiz MT, Duarte JL, Nicoleti LR, Saad STO, Chorilli M. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2021 ; 168 76-89.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/j.ejpb.2021.08.011
Artigo de periodico
Population pharmacokinetics of gabapentin in patients with neuropathic pain: lack of effect of diabetes or glycaemic control (2021)
Costa, Ana Carolina Conchon ; Benzi, Jhohann Richard de Lima ; Yamamoto, Priscila Akemi ; Freitas, Maria Cristina Foss de ; Paula, Francisco Jose Albuquerque de ; Zanelli, Cleslei Fernando; Lauretti, Gabriela Rocha ; Moraes, Natália Valadares
Source: British Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP
Subjects: FARMACOCINÉTICA, DIABETES MELLITUS, DOR, HIPERGLICEMIA, FARMACOLOGIA CLÍNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, Ana Carolina Conchon et al. Population pharmacokinetics of gabapentin in patients with neuropathic pain: lack of effect of diabetes or glycaemic control. British Journal of Clinical Pharmacology, v. 87, n. 4, p. 1981-1989, 2021Tradução . . Disponível em: https://doi.org/10.1111/bcp.14594. Acesso em: 17 nov. 2024.
APA
Costa, A. C. C., Benzi, J. R. de L., Yamamoto, P. A., Freitas, M. C. F. de, Paula, F. J. A. de, Zanelli, C. F., et al. (2021). Population pharmacokinetics of gabapentin in patients with neuropathic pain: lack of effect of diabetes or glycaemic control. British Journal of Clinical Pharmacology, 87( 4), 1981-1989. doi:10.1111/bcp.14594
NLM
Costa ACC, Benzi JR de L, Yamamoto PA, Freitas MCF de, Paula FJA de, Zanelli CF, Lauretti GR, Moraes NV. Population pharmacokinetics of gabapentin in patients with neuropathic pain: lack of effect of diabetes or glycaemic control [Internet]. British Journal of Clinical Pharmacology. 2021 ; 87( 4): 1981-1989.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1111/bcp.14594
Vancouver
Costa ACC, Benzi JR de L, Yamamoto PA, Freitas MCF de, Paula FJA de, Zanelli CF, Lauretti GR, Moraes NV. Population pharmacokinetics of gabapentin in patients with neuropathic pain: lack of effect of diabetes or glycaemic control [Internet]. British Journal of Clinical Pharmacology. 2021 ; 87( 4): 1981-1989.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1111/bcp.14594
Artigo de periodico
A review of analytical methods for the determination of tibolone: pharmacokinetics and pharmaceutical formulations analysis and application in doping control (2021)
Angelo, Marilene Lopes; Moreira, Fernanda de Lima ; Santos, Ana Laura Araújo; Salgado, Hérida Regina Nunes; Araújo, Magali Benjamim de
Source: Current Pharmaceutical Analysis. Unidade: FCFRP
Subjects: TERAPIA DA REPOSIÇÃO HORMONAL, CROMATOGRAFIA LÍQUIDA DE ALTA EFICIÊNCIA, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANGELO, Marilene Lopes et al. A review of analytical methods for the determination of tibolone: pharmacokinetics and pharmaceutical formulations analysis and application in doping control. Current Pharmaceutical Analysis, v. 17, n. 1, p. 31-39, 2021Tradução . . Disponível em: https://doi.org/10.2174/1573412916666191025143214. Acesso em: 17 nov. 2024.
APA
Angelo, M. L., Moreira, F. de L., Santos, A. L. A., Salgado, H. R. N., & Araújo, M. B. de. (2021). A review of analytical methods for the determination of tibolone: pharmacokinetics and pharmaceutical formulations analysis and application in doping control. Current Pharmaceutical Analysis, 17( 1), 31-39. doi:10.2174/1573412916666191025143214
NLM
Angelo ML, Moreira F de L, Santos ALA, Salgado HRN, Araújo MB de. A review of analytical methods for the determination of tibolone: pharmacokinetics and pharmaceutical formulations analysis and application in doping control [Internet]. Current Pharmaceutical Analysis. 2021 ; 17( 1): 31-39.[citado 2024 nov. 17 ] Available from: https://doi.org/10.2174/1573412916666191025143214
Vancouver
Angelo ML, Moreira F de L, Santos ALA, Salgado HRN, Araújo MB de. A review of analytical methods for the determination of tibolone: pharmacokinetics and pharmaceutical formulations analysis and application in doping control [Internet]. Current Pharmaceutical Analysis. 2021 ; 17( 1): 31-39.[citado 2024 nov. 17 ] Available from: https://doi.org/10.2174/1573412916666191025143214
Artigo de periodico
Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics (2021)
Pippa, Leandro Francisco ; Pereira, Maria Paula Marques ; Silva, Anna Christina Tojal da; Vilar, Fernando Crivelenti; Haes, Tissiana Marques de; Fonseca, Benedito Antonio Lopes da; Martinez, Roberto ; Coelho, Eduardo Barbosa ; Wichert-Ana, Lauro; Lanchote, Vera Lucia
Source: Frontiers in Chemistry. Unidades: FCFRP, FMRP, EERP
Subjects: ANTIFÚNGICOS, LÍQUIDO CEFALORRAQUIDIANO, FARMACOCINÉTICA, PLASMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics. Frontiers in Chemistry, v. 9, p. 1-14, 2021Tradução . . Disponível em: https://doi.org/10.3389/fchem.2021.782131. Acesso em: 17 nov. 2024.
APA
Pippa, L. F., Pereira, M. P. M., Silva, A. C. T. da, Vilar, F. C., Haes, T. M. de, Fonseca, B. A. L. da, et al. (2021). Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics. Frontiers in Chemistry, 9, 1-14. doi:10.3389/fchem.2021.782131
NLM
Pippa LF, Pereira MPM, Silva ACT da, Vilar FC, Haes TM de, Fonseca BAL da, Martinez R, Coelho EB, Wichert-Ana L, Lanchote VL. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics [Internet]. Frontiers in Chemistry. 2021 ; 9 1-14.[citado 2024 nov. 17 ] Available from: https://doi.org/10.3389/fchem.2021.782131
Vancouver
Pippa LF, Pereira MPM, Silva ACT da, Vilar FC, Haes TM de, Fonseca BAL da, Martinez R, Coelho EB, Wichert-Ana L, Lanchote VL. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics [Internet]. Frontiers in Chemistry. 2021 ; 9 1-14.[citado 2024 nov. 17 ] Available from: https://doi.org/10.3389/fchem.2021.782131
Artigo de periodico
PK/PD approach to evaluate Meropenem effectiveness in critically ill burn adolescents versus young adults undergoing therapy of septic shock (2021)
Camargo, Thais Vieira de; Silva Júnior, João Manoel da; Silva Junior, Elson Mendes da; Santos, Verônica Jorge; Rocha, Adriana; Lanchote, Vera Lucia ; Santos, Silvia Regina Cavani Jorge ; Gomez, David de Souza
Source: Brazilian Journal of Health Review. Unidades: FM, FCFRP, FCF
Subjects: FARMACOCINÉTICA, FARMACODINÂMICA, CHOQUE SÉPTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMARGO, Thais Vieira de et al. PK/PD approach to evaluate Meropenem effectiveness in critically ill burn adolescents versus young adults undergoing therapy of septic shock. Brazilian Journal of Health Review, v. 4, n. 1, p. 1213-1232, 2021Tradução . . Disponível em: https://doi.org/10.34119/bjhrv4n1-107. Acesso em: 17 nov. 2024.
APA
Camargo, T. V. de, Silva Júnior, J. M. da, Silva Junior, E. M. da, Santos, V. J., Rocha, A., Lanchote, V. L., et al. (2021). PK/PD approach to evaluate Meropenem effectiveness in critically ill burn adolescents versus young adults undergoing therapy of septic shock. Brazilian Journal of Health Review, 4( 1), 1213-1232. doi:10.34119/bjhrv4n1-107
NLM
Camargo TV de, Silva Júnior JM da, Silva Junior EM da, Santos VJ, Rocha A, Lanchote VL, Santos SRCJ, Gomez D de S. PK/PD approach to evaluate Meropenem effectiveness in critically ill burn adolescents versus young adults undergoing therapy of septic shock [Internet]. Brazilian Journal of Health Review. 2021 ; 4( 1): 1213-1232.[citado 2024 nov. 17 ] Available from: https://doi.org/10.34119/bjhrv4n1-107
Vancouver
Camargo TV de, Silva Júnior JM da, Silva Junior EM da, Santos VJ, Rocha A, Lanchote VL, Santos SRCJ, Gomez D de S. PK/PD approach to evaluate Meropenem effectiveness in critically ill burn adolescents versus young adults undergoing therapy of septic shock [Internet]. Brazilian Journal of Health Review. 2021 ; 4( 1): 1213-1232.[citado 2024 nov. 17 ] Available from: https://doi.org/10.34119/bjhrv4n1-107
Artigo de periodico
Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A (2021)
Tozatto, Eduardo; Benzi, Jhohann Richard de Lima ; Rocha, Adriana; Coelho, Eduardo Barbosa ; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FÁRMACOS, HIPERTENSÃO, FARMACOCINÉTICA, ANTIDEPRESSIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOZATTO, Eduardo et al. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, v. 61, n. 3, p. 319-327, 2021Tradução . . Disponível em: https://doi.org/10.1002/jcph.1745. Acesso em: 17 nov. 2024.
APA
Tozatto, E., Benzi, J. R. de L., Rocha, A., Coelho, E. B., & Lanchote, V. L. (2021). Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, 61( 3), 319-327. doi:10.1002/jcph.1745
NLM
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1002/jcph.1745
Vancouver
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1002/jcph.1745
Artigo de periodico
Andrographis paniculata formulations: impact on diterpene lactone oral bioavailability (2021)
Damasceno, João Paulo Loureiro ; Rosa, Hemerson Silva da; Araújo, Luciana Silva de; Furtado, Niege Araçari Jacometti Cardoso
Source: European Journal of Drug Metabolism and Pharmacokinetics. Unidade: FCFRP
Subjects: PLANTAS MEDICINAIS, FITOTERAPIA, EXTRATOS (FORMAS FARMACÊUTICAS), FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DAMASCENO, João Paulo Loureiro et al. Andrographis paniculata formulations: impact on diterpene lactone oral bioavailability. European Journal of Drug Metabolism and Pharmacokinetics, v. 47, p. 19-30, 2021Tradução . . Disponível em: https://doi.org/10.1007/s13318-021-00736-7. Acesso em: 17 nov. 2024.
APA
Damasceno, J. P. L., Rosa, H. S. da, Araújo, L. S. de, & Furtado, N. A. J. C. (2021). Andrographis paniculata formulations: impact on diterpene lactone oral bioavailability. European Journal of Drug Metabolism and Pharmacokinetics, 47, 19-30. doi:10.1007/s13318-021-00736-7
NLM
Damasceno JPL, Rosa HS da, Araújo LS de, Furtado NAJC. Andrographis paniculata formulations: impact on diterpene lactone oral bioavailability [Internet]. European Journal of Drug Metabolism and Pharmacokinetics. 2021 ; 47 19-30.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1007/s13318-021-00736-7
Vancouver
Damasceno JPL, Rosa HS da, Araújo LS de, Furtado NAJC. Andrographis paniculata formulations: impact on diterpene lactone oral bioavailability [Internet]. European Journal of Drug Metabolism and Pharmacokinetics. 2021 ; 47 19-30.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1007/s13318-021-00736-7
Artigo de periodico
Natural products-based drug design against SARS-CoV-2 Mpro 3CLpro (2021)
Silva, Rai Campos ; Freitas, Humberto F.; Campos, Joaquín M.; Kimani, Njogu M.; Silva, Carlos Henrique Tomich de Paula da ; Borges, Rosivaldo S.; Pita, Samuel S. R.; Santos, Cleydson B. R.
Source: International Journal of Molecular Sciences. Unidades: FCFRP, FFCLRP
Subjects: COVID-19, PRODUTOS NATURAIS, SAÚDE PÚBLICA, FARMACOCINÉTICA, ANÁLISE TOXICOLÓGICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Rai Campos et al. Natural products-based drug design against SARS-CoV-2 Mpro 3CLpro. International Journal of Molecular Sciences, v. 22, n. 21, p. 1-24, 2021Tradução . . Disponível em: https://doi.org/10.3390/ijms222111739. Acesso em: 17 nov. 2024.
APA
Silva, R. C., Freitas, H. F., Campos, J. M., Kimani, N. M., Silva, C. H. T. de P. da, Borges, R. S., et al. (2021). Natural products-based drug design against SARS-CoV-2 Mpro 3CLpro. International Journal of Molecular Sciences, 22( 21), 1-24. doi:10.3390/ijms222111739
NLM
Silva RC, Freitas HF, Campos JM, Kimani NM, Silva CHT de P da, Borges RS, Pita SSR, Santos CBR. Natural products-based drug design against SARS-CoV-2 Mpro 3CLpro [Internet]. International Journal of Molecular Sciences. 2021 ; 22( 21): 1-24.[citado 2024 nov. 17 ] Available from: https://doi.org/10.3390/ijms222111739
Vancouver
Silva RC, Freitas HF, Campos JM, Kimani NM, Silva CHT de P da, Borges RS, Pita SSR, Santos CBR. Natural products-based drug design against SARS-CoV-2 Mpro 3CLpro [Internet]. International Journal of Molecular Sciences. 2021 ; 22( 21): 1-24.[citado 2024 nov. 17 ] Available from: https://doi.org/10.3390/ijms222111739
Artigo de periodico
HPLC methods for choloroquine determination in biological samples and pharmaceutical products (2021)
Martins, Yugo Araújo ; Gonçalves, Talita Mota; Lopez, Renata Fonseca Vianna
Source: DARU Journal of Pharmaceutical Sciences. Unidade: FCFRP
Subjects: ANTIMALÁRICOS, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, MONITORAMENTO BIOLÓGICO, CROMATOGRAFIA LÍQUIDA DE ALTA EFICIÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARTINS, Yugo Araújo e GONÇALVES, Talita Mota e LOPEZ, Renata Fonseca Vianna. HPLC methods for choloroquine determination in biological samples and pharmaceutical products. DARU Journal of Pharmaceutical Sciences, v. 29, n. 1, p. 223-239, 2021Tradução . . Disponível em: https://doi.org/10.1007/s40199-021-00391-y. Acesso em: 17 nov. 2024.
APA
Martins, Y. A., Gonçalves, T. M., & Lopez, R. F. V. (2021). HPLC methods for choloroquine determination in biological samples and pharmaceutical products. DARU Journal of Pharmaceutical Sciences, 29( 1), 223-239. doi:10.1007/s40199-021-00391-y
NLM
Martins YA, Gonçalves TM, Lopez RFV. HPLC methods for choloroquine determination in biological samples and pharmaceutical products [Internet]. DARU Journal of Pharmaceutical Sciences. 2021 ; 29( 1): 223-239.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1007/s40199-021-00391-y
Vancouver
Martins YA, Gonçalves TM, Lopez RFV. HPLC methods for choloroquine determination in biological samples and pharmaceutical products [Internet]. DARU Journal of Pharmaceutical Sciences. 2021 ; 29( 1): 223-239.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1007/s40199-021-00391-y
Artigo de periodico-carta/editorial
Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] (2020)
Gonçalves, Paulo Vinícius Bernardes; Moreira, Fernanda de Lima; Benzi, Jhohann Richard de Lima ; Cavalli, Ricardo de Carvalho; Duarte, Geraldo; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FARMACOCINÉTICA, TRABALHO DE PARTO INDUZIDO, HIPERTENSÃO NA GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GONÇALVES, Paulo Vinícius Bernardes et al. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/jcph.1719. Acesso em: 17 nov. 2024. , 2020
APA
Gonçalves, P. V. B., Moreira, F. de L., Benzi, J. R. de L., Cavalli, R. de C., Duarte, G., & Lanchote, V. L. (2020). Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1002/jcph.1719
NLM
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1002/jcph.1719
Vancouver
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1002/jcph.1719
Artigo de periodico
Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study (2020)
Pinto, Leonardo Santos Ribeiro; Vale, Gabriel Tavares do ; Moreira, Fernanda de Lima ; Pereira, Maria Paula Marques ; Coelho, Eduardo Barbosa ; Cavalli, Ricardo de Carvalho ; Lanchote, Vera Lucia
Source: Journal of Chromatography B. Unidades: FCFRP, FMRP, EERP
Subjects: ANTI-HISTAMÍNICOS, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, PLASMA, GRAVIDEZ, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, v. 1145, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2020.122094. Acesso em: 17 nov. 2024.
APA
Pinto, L. S. R., Vale, G. T. do, Moreira, F. de L., Pereira, M. P. M., Coelho, E. B., Cavalli, R. de C., & Lanchote, V. L. (2020). Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, 1145. doi:10.1016/j.jchromb.2020.122094
NLM
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Vancouver
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Artigo de periodico
Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio (2020)
Pippa, Leandro Francisco ; Oliveira, Milena Locci de ; Rocha, Adriana; Andrade, Jurandyr Moreira de ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: ANTINEOPLÁSICOS, FARMACOCINÉTICA, VARIAÇÃO (BIOLOGIA), NEOPLASIAS MAMÁRIAS, MIOCARDIOPATIA CONGESTIVA, QUIMIOTERAPIA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, v. 185, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113231. Acesso em: 17 nov. 2024.
APA
Pippa, L. F., Oliveira, M. L. de, Rocha, A., Andrade, J. M. de, & Lanchote, V. L. (2020). Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, 185. doi:10.1016/j.jpba.2020.113231
NLM
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/j.jpba.2020.113231
Vancouver
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/j.jpba.2020.113231

USP Schools

ReP

Filtros

Document Types

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Publisher

Conference titles

Countries/Territories

Funding Agencies

Indexado em

Normalized affiliation

Non normalized affiliation

Countries of institutions of collaboration